CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,018 enrolled
Drug / intervention
Endeavor® Zotarolimus Eluting Coronary Stent Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00846846
NCT00846846Phase 4Completed
CompareCT.gov

Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial

Medtronic Vascular·interventional·Posted Feb 19, 2009·Updated May 4, 2015

In Brief

A Phase 4 clinical trial evaluating Endeavor® Zotarolimus Eluting Coronary Stent System for Coronary Artery Disease, Autosomal Dominant, 1. Completed, enrolled 1,018 participants across 1 site.

Detailed Summary

In order to expand safety information in patients treated with the Endeavor Drug Eluting Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT Trial. The amended study is "PROTECT CONTINUED ACCESS" ("PROTECT CA").

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Autosomal Dominant, 1
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 19, 2009
Enrollment StartJan 1, 2009
Primary CompletionMar 1, 2013
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.4 years ago

Interventions

Endeavor® Zotarolimus Eluting Coronary Stent Systemdevice

Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation